Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi
therapeutics company, today announced that management will present a
company overview at the Morgan Stanley Global Healthcare Unplugged
Conference on Tuesday, September 9, 2008, at 3:55 p.m. ET at the Grand
Hyatt New York in New York City.
A live audio webcast of the presentation will be available on the “Investors”
section of the company’s website, www.alnylam.com.
A replay of the presentation will be available on the Alnylam website
within 48 hours after the event and will be archived for 14 days.
About Alnylam
Alnylam is a biopharmaceutical company developing novel therapeutics
based on RNA interference, or RNAi. The company is applying its
therapeutic expertise in RNAi to address significant medical needs, many
of which cannot effectively be addressed with small molecules or
antibodies, the current major classes of drugs. Alnylam is leading the
translation of RNAi as a new class of innovative medicines with
peer-reviewed research efforts published in the world’s
top scientific journals including Nature, Nature Medicine,
and Cell. The company is leveraging these capabilities to build a
broad pipeline of RNAi therapeutics; its most advanced program is in
Phase II human clinical trials for the treatment of respiratory
syncytial virus (RSV) infection. In addition, the company is developing
RNAi therapeutics for the treatment of a wide range of disease areas,
including liver cancers, hypercholesterolemia, and Huntington’s
disease. The company’s leadership position in
fundamental patents, technology, and know-how relating to RNAi has
enabled it to form major alliances with leading companies including
Medtronic, Novartis, Biogen Idec, Roche, Takeda, and Kyowa Hakko Kogyo.
To reflect its outlook for key scientific, clinical, and business
initiatives, Alnylam has established “RNAi
2010” which includes the company’s
plan to significantly expand the scope of delivery solutions for RNAi
therapeutics, have four or more programs in clinical development, and to
form four or more new major business collaborations, all by the end of
2010. Alnylam is a joint owner of Regulus Therapeutics LLC, a joint
venture focused on the discovery, development, and commercialization of
microRNA therapeutics. Founded in 2002, Alnylam maintains headquarters
in Cambridge, Massachusetts. For more information, visit www.alnylam.com.
Alnylam Pharmaceuticals, Inc.
Cynthia Clayton, 617-551-8207
(Investors)
or
KMorrisPR
Kathryn Morris,
845-635-9828(Media)
